

[KX 825]

SEPTEMBER 2010

Sub. Code: 3825

DOCTOR OF PHARMACY (PHARM. D / POST BACCALAUREATE)

DEGREE EXAMINATION

(Regulations 2008-2009)

(Candidates admitted from 2008-2009 onwards)

FIFTH YEAR

PAPER I – CLINICAL RESEARCH

Q.P. Code: 383825

Time: Three Hours

Maximum: 70 marks

Answer ALL questions

I. Elaborate on:

(2 x 20 = 40)

1. Define Clinical Trials?

Discuss in detail five various phases involved in drug development process.

2. Discuss the composition, responsibilities and procedures of IRB/IEC.

II. Write notes on:

(6 x 5 = 30)

1. Significance of post marketing surveillance.

2. Roles and responsibilities of Investigations.

3. Study designs in a clinical trial.

4. Informed consent process.

5. ICH guidelines in clinical trials.

6. Purposes of an audit in a clinical trial.

DOCTOR OF PHARMACY (PHARM. D / POST BACCALAUREATE)**DEGREE EXAMINATION****FIFTH YEAR****PAPER I – CLINICAL RESEARCH****Q.P. Code: 383825****Time: Three Hours****Maximum: 100 marks****Answer ALL questions in the same order.****I. Elaborate on :****Pages Time Marks
(Max.) (Max.) (Max.)**

- | | | | |
|---|----|---------|----|
| 1. a) Define investigational new drug application and describes the component and categories of investigational new drug application. | 17 | 40 min. | 20 |
| b) What are the essential documents for the conducting of clinical trials and its purpose? | | | |
| 2. a) Roles and responsibilities of auditors in clinical research | | | |
| b) Define serious adverse event in clinical trial and responsibilities of investigators in reporting | 17 | 40 min. | 20 |

II. Write notes on :

- | | | | |
|--|---|---------|---|
| 1. Various phases of clinical trial. | 4 | 10 min. | 6 |
| 2. Informed consent process. | 4 | 10 min. | 6 |
| 3. Central drug standard control organisation and food and drug administration. | 4 | 10 min. | 6 |
| 4. Investigators brochure. | 4 | 10 min. | 6 |
| 5. Randomization. | 4 | 10 min. | 6 |
| 6. Source documents in clinical trial. | 4 | 10 min. | 6 |
| 7. Vulnerable subjects. | 4 | 10 min. | 6 |
| 8. Roles and responsibilities of regulatory authority in relation to clinical trial. | 4 | 10 min. | 6 |
| 9. What are the responsibilities of clinical data manager? | 4 | 10 min. | 6 |
| 10. Define the followings: | | | |
| (i) Blinding (ii) Comparator (iii) Good clinical practice. | 4 | 10 min. | 6 |

[LB 825]

OCTOBER 2012

Sub. Code: 3825

PHARM. D / POST BACCALAUREATE DEGREE EXAMS

FIFTH YEAR

PAPER I – CLINICAL RESEARCH

Q.P. Code : 383825

Time : 3 hours
(180 Min)

Maximum : 100 marks

Answer ALL questions in the same order.

I. Elaborate on :

Pages Time Marks
(Max.)(Max.)(Max.)

- | | | | |
|--|----|----|----|
| 1. (A) Explain in details about the institutional review board / independent ethics committee compositions and its functions in clinical research. | 17 | 40 | 20 |
| (B) Define clinical trial and various phases. | | | |
| 2. (A) what are the ethical guidelines in clinical research? | 17 | 40 | 20 |
| (B) Define data management and its component in clinical trials. | | | |

II. Write Notes on :

- | | | | |
|---|---|----|---|
| 1. Protocol and its components. | 4 | 10 | 6 |
| 2. Roles and responsibilities of sponsor in clinical trials. | 4 | 10 | 6 |
| 3. Define investigational new drug application and its procedure for submission. | 4 | 10 | 6 |
| 4. Clinical research co ordinator. | 4 | 10 | 6 |
| 5. Post marketing surveillance and its methods. | 4 | 10 | 6 |
| 6. Role of auditors in clinical trial. | 4 | 10 | 6 |
| 7. What are the roles and responsibilities of sponsor in reporting of serious adverse events? | 4 | 10 | 6 |
| 8. Electronic data capturing system and its role in clinical trial. | 4 | 10 | 6 |
| 9. Protocol amendment in clinical research. | 4 | 10 | 6 |
| 10. Data migration and archiving. | 4 | 10 | 6 |

[KD 825]

OCTOBER 2013

Sub. Code: 3825

DOCTOR OF PHARMACY (PHARM. D / POST BACCALAUREATE)

DEGREE EXAMINATION

FIFTH YEAR

PAPER I – CLINICAL RESEARCH

Q.P. Code: 383825

Time: Three Hours

Maximum: 70 marks

Answer All questions

I. Elaborate on:

(2 x 20 = 40)

1. What is ANDA?

What are the drugs come under ANDA?

What is meant by generic drugs?

Write a note on post marketing surveillance.

2. What is Institutional human ethical committee?

Give the composition, qualification required for the members.

Explain the functions of the committee.

II. Write notes on:

(10 x 3 = 30)

1. Explain the importance of Pharmacological information in drug discovery.

2. Name various chemical characteristics of the drug.

3. Write a not on GCP.

4. What are the challenges faced by the investigator in clinical trials.

5. Write a not on schedule Y.

6. Explain the responsibility of the auditors in clinical trials.

7. Explain the protocol involved in data management in clinical research.

8. Differentiate Phase II & Phase III clinical trials.

9. Why randomization is important in clinical research?

10. Write the significance of preclinical testing in clinical research.

DOCTOR OF PHARMACY (PHARM. D / POST BACCALAUREATE)

DEGREE EXAMINATION

FIFTH YEAR

PAPER I – CLINICAL RESEARCH

Q.P. Code: 383825

Time: Three Hours

Maximum: 70 marks

Answer All questions

I. Elaborate on:

(2 x 20 = 40)

1. a) What is clinical research and why do we need to conduct research?
b) What are the different stages of drug development process?
2. a) Roles and responsibilities of contract research organizations in clinical research.
b) Define Investigator's brochure and describes about its components.

II. Write notes on:

(10 x 3 = 30)

1. Good clinical practice and its principles.
2. Informed consent process.
3. Central drug standard control organisation and food and drug administration.
4. Various ethical guidelines in clinical research.
5. Safety monitoring in clinical trials.
6. Source documents in clinical trial.
7. Vulnerable subjects.
8. Roles and responsibilities of Investigator in clinical trial.
9. What are the responsibilities of regulatory authority in clinical research?
10. Define the followings:
 - a) Case report form (CRF).
 - b) Impartial witness.
 - c) Schedule-Y.

DOCTOR OF PHARMACY (PHARM. D / POST BACCALAUREATE)

DEGREE EXAMINATION

(2009-2010 Regulation)

FIFTH YEAR

PAPER I – CLINICAL RESEARCH

Q.P. Code: 383825

Time: Three Hours

Maximum: 70 marks

Answer All questions

I. Elaborate on:

(4 x 10 = 40)

1. Define investigational new drug application and describes the component and categories of investigational new drug application.
2. Discuss in detail the overview of regulatory environment in Europe.
3. Explain in detail the roles and responsibilities of regulatory authority and contract research coordinators.
4. Describe in detail the various approaches to drug discovery.

II. Write notes on:

(6 x 5 = 30)

1. Write short note on various phases of clinical trials.
2. Describe briefly the ethical guidelines in clinical research.
3. Write a note on data management and its components.
4. Explain briefly the ICH guidelines.
5. Write note on informed consent process.
6. Post marketing surveillance.

DOCTOR OF PHARMACY (PHARM. D / POST BACCALAUREATE)

DEGREE EXAMINATION

(2009-2010 Regulation)

FIFTH YEAR

PAPER I – CLINICAL RESEARCH

Q.P. Code: 383825

Time: Three Hours

Maximum: 70 marks

Answer All questions

I. Elaborate on:

(4 x 10 = 40)

1. Briefly write on:

- a) Double blind clinical trials.
- b) Open label clinical trials.
- c) Retrospective studies.

2. What is mean by informed consent?

Explain content and method of administration of informed consent as per regulatory authorities in clinical trials.

3. What are dosage forms? Give example. Explain different type of dosage forms.

4. Explain the protocols and method of reporting ADR under Pharmacovigilance.

II. Write notes on:

(6 x 5 = 30)

1. How SOPs are prepared to meet the GLP standards?

2. Write the ethical consideration in the conduct of clinical trials.

3. Write a note on safety monitoring in clinical trials.

4. What are the major challenges observed in implementation of the regulatory guidelines in clinical trials?

5. Briefly write the data management in clinical trials.

6. Explain:

- a) Placebo.
- b) Human Subjects.
- c) Candidate drug.

[LH 825]

OCTOBER 2015

Sub. Code: 3825

**PHARM. 'D' AND PHARM. 'D' (POST BACCALAUREATE)
DEGREE EXAMINATION
(2009-2010 Regulation)**

FIFTH YEAR

PAPER I – CLINICAL RESEARCH

Q.P. Code : 383825

Time: Three Hours

Maximum: 70 marks

Answer ALL questions

I. Elaborate on :

(4 x 10 = 40)

1. Define Clinical Trials. Discuss in detail five various phases involved in drug development process.
2. What are the essential documents for the conducting of clinical trials and its purpose?
3. What is Institutional human ethical committee? Give the composition, qualification required for the members and explain the functions of the committee.
4. Discuss the roles and responsibilities of auditors in clinical research.

II. Write notes on :

(6 x 5 = 30)

1. Write in detail the central drug standard control organization guidelines.
2. Explain briefly the informed consent process.
3. Write a note on data management.
4. Describe briefly the ethical guidelines in clinical research.
5. Write briefly the Source documents in clinical trial.
6. What are the responsibilities of clinical data manager?

[LI 825]

APRIL 2016

Sub. Code: 3825

**PHARM. 'D' AND PHARM. 'D' (POST BACCALAUREATE)
DEGREE EXAMINATION
(2009-2010 Regulation)
FIFTH YEAR
PAPER I – CLINICAL RESEARCH**

Q.P. Code : 383825

Time : Three hours

Maximum : 70 Marks

I. Elaborate on:

(4 x 10 = 40)

1. Explain the Pharmacological and Toxicological approaches to Drug discovery.
2. Describe the roles and responsibilities of Investigators and Clinical Research associates.
3. Discuss the challenges in the implementation of Good Clinical Practice guidelines.
4. Describe the guidelines of Central drug standard control organization.

II. Write notes on:

(6 x 5 = 30)

1. Abbreviated New Drug Application.
2. Various types of post marketing surveillance.
3. Ethical principles in Clinical research.
4. Explain the contents in Investigational new drug application.
5. Safety monitoring in Clinical research.
6. Responsibilities of Institutional review board.

[LJ 825]

OCTOBER 2016

Sub. Code: 3825

**PHARM. 'D' AND PHARM. 'D' (POST BACCALAUREATE)
DEGREE EXAMINATION
(2009-2010 Regulation)
FIFTH YEAR
PAPER I – CLINICAL RESEARCH**

Q.P. Code: 383825

Time: Three hours

Maximum : 70 Marks

I. Elaborate on:

(4 x 10 = 40)

1. Discuss in detail the overview of regulatory environment in Europe and USA.
2. What is informed consent? Explain content of informed consent as per regulatory authorities in clinical trials.
3. What are the different methods of post marketing surveillance?
4. Discuss the importance of safety monitoring in clinical trials.

II. Write notes on:

(6 x 5 = 30)

1. Briefly write on Case Report Form.
2. Role and responsibility of clinical research co-ordinator.
3. Write note on Impartial witness.
4. Purpose of an audit in clinical trial.
5. Investigational new drug application.
6. Why randomization is important in clinical research?

[LK 825]

MAY 2017

Sub. Code: 3825

**PHARM. 'D' AND PHARM. 'D' (POST BACCALAUREATE)
DEGREE EXAMINATION
(2009-2010 Regulation)
FIFTH YEAR
PAPER I – CLINICAL RESEARCH**

Q.P. Code : 383825

Time : Three hours

Maximum : 70 Marks

I. Elaborate on:

(4 x 10 = 40)

1. What are the essential documents for the conducting of clinical trials and discuss the purpose of the same?
2. Explain the functions of IRB in clinical research.
3. Define Investigator's brochure and describe about its components.
4. Elaborate on the roles and responsibilities of regulatory authority in relation to clinical trial.

II. Write notes on:

(6 x 5 = 30)

1. Write a note on GCP.
2. Explain the importance of pharmacological information in drug discovery.
3. Preclinical testing in clinical research.
4. Informed Consent Process.
5. Safety monitoring in clinical trials.
6. Explain briefly the ICH guidelines.

[LL 825]

OCTOBER 2017

Sub. Code: 3825

**PHARM. 'D' AND PHARM. 'D' (POST BACCALAUREATE)
DEGREE EXAMINATION
(2009-2010 Regulation)
FIFTH YEAR
PAPER I – CLINICAL RESEARCH**

Q.P. Code : 383825

Time : Three hours

Maximum : 70 Marks

I. Elaborate on:

(4 x 10 = 40)

1. Define Clinical trials. Discuss in detail about the various phases involved in Clinical trial and detail.
2. Discuss in detail about various approaches of Drug discovery.
3. Role and responsibilities of principal investigator in clinical trials.
4. Define Investigational New Drug Application (INDA) and discuss the components and categories of INDA in detail.

II. Write notes on:

(6 x 5 = 30)

1. Post marketing surveillance.
2. Write note on Schedule – Y.
3. Safety monitoring in clinical trials.
4. Discuss in brief about different dosage forms.
5. Preparation of Informed Consent Form (ICF).
6. Role and responsibilities of data management team in clinical trials.

THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY

[LM 825]

MAY 2018

Sub. Code: 3825

**PHARM. 'D' AND PHARM. 'D' (POST BACCALAUREATE)
DEGREE EXAMINATION
(2009-2010 Regulation)
FIFTH YEAR
PAPER I – CLINICAL RESEARCH**

Q.P. Code : 383825

Time : Three hours

Maximum : 70 Marks

I. Elaborate on:

(4 x 10 = 40)

1. Define Bias. Discuss in detail about various sources of bias and methods to avoid Bias.
2. Describe in detail about regulatory setup that governs the clinical research process in India.
3. Explain the components of clinical research protocol and the process of protocol preparation.
4. Discuss in detail about various methods used in post marketing safety monitoring process.

II. Write notes on:

(6 x 5 = 30)

1. Write a note on general parameters involved in inclusion and exclusion criteria.
2. Write the responsibilities of sponsor's in clinical trial.
3. Write the functions of data and safety monitoring board.
4. Define IND application and write contents of IND application.
5. Write a short note on drug discovery process.
6. Write the safety issues on the investigational new drugs.

THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY

[LN 825]

OCTOBER 2018

Sub. Code: 3825

**PHARM. 'D' AND PHARM. 'D' (POST BACCALAUREATE)
DEGREE EXAMINATION
(2009-2010 Regulation)
FIFTH YEAR
PAPER I – CLINICAL RESEARCH**

Q.P. Code : 383825

Time : Three hours

Maximum : 70 Marks

I. Elaborate on:

(4 x 10 = 40)

1. Describe the types of control and significance of using control in clinical trials.
2. Write the essential elements of informed consent form and problems in informed consent.
3. Discuss in detail about role and responsibilities of principal investigator in clinical research.
4. Explain components of ICH-GCP guidelines and write its significance.

II. Write notes on:

(6 x 5 = 30)

1. Define randomization. Write a note on static and adaptive designs.
2. Write about functions of various regulatory divisions of US-FDA.
3. Write a short note on investigators brochure.
4. List the type of audits and its importance in clinical trials.
5. Write a note on new drug application submission.
6. Define parallel and cross over study designs of clinical research.

THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY

[LO 825]

MAY 2019

Sub. Code: 3825

**PHARM. 'D' AND PHARM. 'D' (POST BACCALAUREATE)
DEGREE EXAMINATION
(2009-2010 Regulation)
FIFTH YEAR
PAPER I – CLINICAL RESEARCH**

Q.P. Code : 383825

Time : Three hours

Maximum : 70 Marks

I. Elaborate on:

(4 x 10 = 40)

1. Describe the importance and requirements of various phases of clinical trials.
2. Discuss in detail about the role and responsibilities of clinical research associate.
3. Describe the clinical trial data management process and its benefits.
4. Explain in detail about essential documents of clinical research process.

II. Write notes on:

(6 x 5 = 30)

1. Write a note on blinding and un-blinding.
2. Give a note on constitution and responsibilities of institutional review board.
3. Write a brief note on case record form.
4. Write a short note on regulatory setup in Europe.
5. Briefly write about study site audits and its significance.
6. Write a short note on informed consent process.

THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY

[LP 825]

OCTOBER 2019

Sub. Code: 3825

PHARM. 'D' AND PHARM. 'D' (POST BACCALAUREATE)

DEGREE EXAMINATION

(2009-2010 Regulation)

FIFTH YEAR

PAPER I – CLINICAL RESEARCH

Q.P. Code : 383825

Time : Three hours

Maximum : 70 Marks

I. Elaborate on:

(4 x 10 = 40)

1. Write about the ICH guidelines in clinical trials.
2. Describe the various pharmacological and toxicological approaches to drug discovery.
3. Give an account on Abbreviated New drug Application.
4. Discuss the roles and responsibilities of sponsors and investigators in clinical research.

II. Write notes on:

(6 x 5 = 30)

1. Regulatory environment in India.
2. Vulnerable subjects.
3. Challenges in implementation of guidelines in clinical trials.
4. Responsibilities of clinical research coordinator in clinical research.
5. Case Report form in study design.
6. Significance of Post marketing surveillance.

THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY

[PHARMD 0321]

MARCH 2021

Sub. Code: 3825

(OCTOBER 2020 EXAM SESSION)

PHARM. 'D' (POST BACCALAUREATE)

DEGREE EXAMINATION

FIFTH YEAR (2009-2010 Regulation)

PAPER I – CLINICAL RESEARCH

Q.P. Code : 383825

Time : Three hours

Maximum : 70 Marks

I. Elaborate on:

(4 x 10 = 40)

1. Explain the Pharmacological and Toxicological approaches to Drug discovery.
2. Define Investigator's brochure and describe about its components.
3. What are dosage forms? Give example. Explain different type of dosage forms.
4. Explain Bias and discuss in detail about various sources of bias and methods to avoid Bias.

II. Write notes on:

(6 x 5 = 30)

1. How SOPs are prepared to meet the Good Laboratory Practices standards?
2. Write the ethical consideration in the conduct of Clinical trials.
3. Write the safety issues on the investigational new drugs.
4. What are the major challenges observed in implementation of the regulatory guidelines in clinical trials?
5. Write a note on schedule Y.
6. What is Randomization? Brief about static and adaptive designs.

THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY

[PHARMD 0122]

**JANUARY 2022
(OCTOBER 2021 EXAM SESSION)**

Sub. Code: 3825

**PHARM 'D' AND PHARM. 'D' (POST BACCALAUREATE) DEGREE EXAMINATION
FIFTH YEAR (2009-2010 Regulation)
PAPER I – CLINICAL RESEARCH
Q.P. Code : 383825**

Time : Three hours

Answer ALL Questions

Maximum : 70 Marks

I. Elaborate on:

(4 x 10 = 40)

1. Discuss in detail about the overview of regulatory environment in Europe and USA.
2. Define Drug Discovery and development. Explain the various stages of drug development process.
3. Explain in detail the roles and responsibilities of regulatory authority and contract research coordinators.
4. Discuss the importance of safety monitoring in Clinical trials.

II. Write notes on:

(6 x 5 = 30)

1. Investigational New Drug Application.
2. Responsibilities of institutional Review Board.
3. Informed consent process.
4. Purposes of an audit in a Clinical trial.
5. Good clinical practice and its principles.
6. Study designs in a Clinical trial.

THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY

[PHARMD 0522]

MAY 2022

Sub. Code: 3825

(APRIL 2022 EXAM SESSION)

PHARM 'D' and PHARM. 'D' (POST BACCALAUREATE)

DEGREE EXAMINATION

FIFTH YEAR (2009-2010 Regulation)

PAPER I – CLINICAL RESEARCH

Q.P. Code : 383825

Time : Three hours

Maximum : 70 Marks

I. Elaborate on:

(4 x 10 = 40)

1. Describe in detail the various approaches to drug discovery.
2. Discuss in detail the overview of regulatory environment in Europe.
3. Discuss the composition, responsibilities and procedures of Independent ethics committee.
4. Explain the protocols and method of reporting ADR under Pharmacovigilance.

II. Write notes on:

(6 x 5 = 30)

1. Write short note on various phases of clinical trials.
2. Write the responsibilities of auditor in clinical trial.
3. Write a note on data management and its components.
4. What are the major challenges observed in implementation of the regulatory guidelines in clinical trials?
5. Write note on informed consent process.
6. Write briefly the Source documents in clinical trial.

THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY

[PHARMD 1122]

**NOVEMBER 2022
(OCTOBER 2022 EXAM SESSION)**

Sub. Code: 3825

**PHARM 'D' and PHARM. 'D' (POST BACCALAUREATE)
DEGREE EXAMINATION
FIFTH YEAR (2009-2010 Regulation)
PAPER I – CLINICAL RESEARCH
Q.P. Code : 383825**

Time : Three hours

Maximum : 70 Marks

I. Elaborate on:

(4 x 10 = 40)

1. Write the roles and responsibilities of Investigators and contract research coordinators.
2. What is Institutional human ethical committee? Give the composition, qualification required for the members. Explain the functions of the committee.
3. Write a brief note on regulatory environment in Europe.
4. Elaborate on different dosage forms in drug development process.

II. Write notes on:

(6 x 5 = 30)

1. Write note on vulnerable subjects.
2. Importance of post marketing surveillance.
3. Write note on drug characterization.
4. ICH guidelines in clinical trials.
5. What are Source documents in clinical trial?
6. Define the following:
(i) Blinding (ii) Randomization (iii) Good clinical practice.

THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY

[PHARMD 0423]

APRIL 2023

Sub. Code: 3825

**PHARM. 'D' (POST BACCALAUREATE)
DEGREE EXAMINATION
FIFTH YEAR (2009-2010 Regulation)
PAPER I – CLINICAL RESEARCH**

Q.P. Code: 383825

Time : Three hours

Answer ALL Questions

Maximum : 70 Marks

I. Elaborate on:

(4 x 10 = 40)

1. Explain briefly about Ind application and drug characterization.
2. Explain Safety monitoring in clinical trial.
3. Discuss in detail the overview of regulatory environment in Europe and India.
4. Explain the contents in Abbreviated New Drug Application submission.

II. Write notes on:

(6 x 5 = 30)

1. Institutional review board.
2. Ethical guidelines in clinical research.
3. In clinical trials, what are the responsibilities of Auditors?
4. Explain briefly about protocol.
5. Write note on Sponsor.
6. Discuss the challenges in the implementation of Good Clinical Practice guidelines.

THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY

[PHARMD 1023]

OCTOBER 2023

Sub. Code: 3825

**PHARM 'D' AND PHARM. 'D' (POST BACCALAUREATE) DEGREE
EXAMINATION
FIFTH YEAR (2009-2010 Regulation)
PAPER I – CLINICAL RESEARCH**

Q.P. Code: 383825

Time : Three hours

Answer ALL Questions

Maximum : 70 Marks

I. Elaborate on:

(4 x 10 = 40)

1. Describe the composition and functions of IRB.
2. Discuss the different stages of drug development process.
3. Explain the clinical trial data management process and its benefits.
4. Discuss in detail the roles and responsibilities of investigator in clinical research.

II. Write notes on:

(6 x 5 = 30)

1. Types of audit and its significance in clinical research.
2. Investigator's brochure.
3. Case Report Form.
4. Contract Research Coordinators.
5. Vulnerable subjects.
6. Safety issues of investigational new drug.

THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY

[PHARMD 0424]

APRIL 2024

Sub. Code: 3825

**PHARM 'D' AND PHARM. 'D' (POST BACCALAUREATE) DEGREE
EXAMINATION
FIFTH YEAR (2009-2010 Regulation)
PAPER I – CLINICAL RESEARCH**

Q.P. Code: 383825

Time: Three hours

Answer ALL Questions

Maximum: 70 Marks

I. Elaborate on:

(4 x 10 = 40)

1. Explain briefly about drug development process.
2. Data management and its components.
3. Explain the various methods of post marketing surveillance.
4. Write in detail the central drug standard control organization guidelines.

II. Write notes on:

(6 x 5 = 30)

1. Toxicological approaches to drug discovery process.
2. ICH-GCP guidelines.
3. What are the responsibilities of Clinical research associate?
4. Explain the process of Informed consent.
5. Different types of clinical trials.
6. Define the following:
 - a) Case Report Form (CRF)
 - b) Impartial witness
 - c) Schedule-Y

THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY

[PHARMD 1024]

OCTOBER 2024

Sub. Code: 3825

**PHARM 'D' AND PHARM. 'D' (POST BACCALAUREATE) DEGREE
EXAMINATION**

FIFTH YEAR (2009-2010 Regulation)

PAPER I – CLINICAL RESEARCH

Q.P. Code: 383825

Time: Three hours

Answer ALL Questions

Maximum: 70 Marks

I. Elaborate on:

(4 x 10 = 40)

1. Explain the roles and responsibilities of sponsor in clinical research.
2. What are the components and process of preparing a protocol?
3. Describe the salient features of ICH-GCP guidelines.
4. Discuss the various phases of clinical trials.

II. Write notes on:

(6 x 5 = 30)

1. Schedule –Y.
2. Differentiate blinding and unblinding in a clinical trial.
3. Problems faced in informed consent process.
4. Responsibilities of Data and Safety Monitoring Board.
5. Basic components of IND.
6. Significance of Electronic Data Capture system in clinical research.

THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY

[PHARMD 0425]

APRIL 2025

Sub. Code: 3825

**PHARM 'D' AND PHARM. 'D' (POST BACCALAUREATE) DEGREE
EXAMINATION**

FIFTH YEAR (2009-2010 Regulation)

PAPER I – CLINICAL RESEARCH

Q.P. Code: 383825

Time: Three hours

Answer ALL Questions

Maximum: 70 Marks

I. Elaborate on:

(4 x 10 = 40)

1. Describe the process of drug characterization and its importance in drug development.
2. Explain the regulatory environment for clinical research in the USA.
3. Discuss the ethical guidelines in clinical research and their significance.
4. Explain the process of designing clinical study documents, including protocol, CRF and ICF.

II. Write notes on:

(6 x 5 = 30)

1. What is the role of a Clinical Research Associate (CRA) in clinical trials?
2. Define informed consent and explain its significance in clinical research.
3. What are the key responsibilities of auditors in clinical trials?
4. Explain about the Data management.
5. What are the essential components of a Clinical Study Report (CSR)?
6. Explain the importance of Good Clinical Practice (GCP) in drug development.

THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY

[PHARMD 1025]

OCTOBER 2025

Sub. Code: 3825

**PHARM 'D' AND PHARM. 'D' (POST BACCALAUREATE) DEGREE
EXAMINATION**

FIFTH YEAR (2009-2010 Regulation)

PAPER I – CLINICAL RESEARCH

Q.P. Code: 383825

Time: Three hours

Answer ALL Questions

Maximum: 70 Marks

I. Elaborate on:

(4 x 10 = 40)

1. Discuss in detail a responsibilities of Regulatory authority and auditors in Clinical Trial.
2. Define investigational new drug application and explain the components of investigational new drug application.
3. Explain the regulatory setup for monitoring clinical research in India.
4. Describe inform consent process and its significance.

II. Write notes on:

(6 x 5 = 30)

1. Vulnerable population.
2. Various sources of bias in clinical research.
3. Responsibilities of a clinical trial monitor.
4. Importance of source documents.
5. Significance of safety monitoring in clinical research.
6. Role of IRB in conducting a clinical trial.
